Jul 3, 2018
With the rapid generation of biological screening data and the potential for innovative selection of compounds for screening, the importance of multivendor collaborations together with improvements in automation has never been greater in terms of helping the drug discovery community as a whole.
The creation and subsequent development of inhaled biologics has become highly significant as it is now the route of choice for the delivery of numerous drugs. This is especially the case with biopharmaceuticals developed for the treatment of respiratory diseases.
This article was written by Dr Simon Moore, Dr Kirsty Harper & Dr Sylwia Marshall
If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: